Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study

Efrat Luttwak; Moshe E. Gatt; Eyal Lebel; Noa Lavi; Tamar Tadmor; Kreiniz Natalia; Noam Benyamini; Netanel Horowitz; Mika Geva; Celia Suriu; Irit Avivi; Svetlana Trestman; Moshe Mittelman; Ory Rouvio; Yael C. Cohen

doi:10.1016/j.clml.2020.06.002

Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study

Efrat Luttwak^*, Moshe E. Gatt, Eyal Lebel, Noa Lavi, Tamar Tadmor, Kreiniz Natalia, Noam Benyamini, Netanel Horowitz, Mika Geva, Celia Suriu, Irit Avivi, Svetlana Trestman, Moshe Mittelman, Ory Rouvio, Yael C. Cohen

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In a real-life multisite study, bortezomib (BTZ) maintenance therapy administered after a BTZ-based induction, with or without autologous transplantation, was safe, well tolerated, and effective in newly diagnosed myeloma patients. Progression-free survival (PFS) was 45 months, similar to that reported with lenalidomide maintenance therapy. Adverse cytogenetics was associated with worse PFS among patients treated with BTZ induction followed by maintenance therapy, but not in those who additionally underwent transplantation.

Original language	English
Pages (from-to)	e850-e857
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Issue number	11
DOIs	https://doi.org/10.1016/j.clml.2020.06.002
State	Published - Nov 2020
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Inc.

Keywords

Bortezomib
Continuous therapy
Maintenance therapy
Multiple myeloma
Real-life experience

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2020.06.002

Cite this

Luttwak, E., Gatt, M. E., Lebel, E., Lavi, N., Tadmor, T., Natalia, K., Benyamini, N., Horowitz, N., Geva, M., Suriu, C., Avivi, I., Trestman, S., Mittelman, M., Rouvio, O., & Cohen, Y. C. (2020). Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study. Clinical Lymphoma, Myeloma and Leukemia, 20(11), e850-e857. https://doi.org/10.1016/j.clml.2020.06.002

@article{c90db12c45f04e43a142084b169c1f3a,

title = "Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study",

abstract = "In a real-life multisite study, bortezomib (BTZ) maintenance therapy administered after a BTZ-based induction, with or without autologous transplantation, was safe, well tolerated, and effective in newly diagnosed myeloma patients. Progression-free survival (PFS) was 45 months, similar to that reported with lenalidomide maintenance therapy. Adverse cytogenetics was associated with worse PFS among patients treated with BTZ induction followed by maintenance therapy, but not in those who additionally underwent transplantation.",

keywords = "Bortezomib, Continuous therapy, Maintenance therapy, Multiple myeloma, Real-life experience",

author = "Efrat Luttwak and Gatt, {Moshe E.} and Eyal Lebel and Noa Lavi and Tamar Tadmor and Kreiniz Natalia and Noam Benyamini and Netanel Horowitz and Mika Geva and Celia Suriu and Irit Avivi and Svetlana Trestman and Moshe Mittelman and Ory Rouvio and Cohen, {Yael C.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = nov,

doi = "10.1016/j.clml.2020.06.002",

language = "אנגלית",

volume = "20",

pages = "e850--e857",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "11",

}

Luttwak, E, Gatt, ME, Lebel, E, Lavi, N, Tadmor, T, Natalia, K, Benyamini, N, Horowitz, N, Geva, M, Suriu, C, Avivi, I, Trestman, S, Mittelman, M, Rouvio, O & Cohen, YC 2020, 'Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study', Clinical Lymphoma, Myeloma and Leukemia, vol. 20, no. 11, pp. e850-e857. https://doi.org/10.1016/j.clml.2020.06.002

TY - JOUR

T1 - Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients

T2 - A Multisite Real-Life Study

AU - Luttwak, Efrat

AU - Gatt, Moshe E.

AU - Lebel, Eyal

AU - Lavi, Noa

AU - Tadmor, Tamar

AU - Natalia, Kreiniz

AU - Benyamini, Noam

AU - Horowitz, Netanel

AU - Geva, Mika

AU - Suriu, Celia

AU - Avivi, Irit

AU - Trestman, Svetlana

AU - Mittelman, Moshe

AU - Rouvio, Ory

AU - Cohen, Yael C.

PY - 2020/11

Y1 - 2020/11

N2 - In a real-life multisite study, bortezomib (BTZ) maintenance therapy administered after a BTZ-based induction, with or without autologous transplantation, was safe, well tolerated, and effective in newly diagnosed myeloma patients. Progression-free survival (PFS) was 45 months, similar to that reported with lenalidomide maintenance therapy. Adverse cytogenetics was associated with worse PFS among patients treated with BTZ induction followed by maintenance therapy, but not in those who additionally underwent transplantation.

AB - In a real-life multisite study, bortezomib (BTZ) maintenance therapy administered after a BTZ-based induction, with or without autologous transplantation, was safe, well tolerated, and effective in newly diagnosed myeloma patients. Progression-free survival (PFS) was 45 months, similar to that reported with lenalidomide maintenance therapy. Adverse cytogenetics was associated with worse PFS among patients treated with BTZ induction followed by maintenance therapy, but not in those who additionally underwent transplantation.

KW - Bortezomib

KW - Continuous therapy

KW - Maintenance therapy

KW - Multiple myeloma

KW - Real-life experience

UR - http://www.scopus.com/inward/record.url?scp=85087285251&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2020.06.002

DO - 10.1016/j.clml.2020.06.002

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 32624446

AN - SCOPUS:85087285251

SN - 2152-2650

VL - 20

SP - e850-e857

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 11

ER -

Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this